PCRX Pacira BioSciences, Inc.
$25.36▲ +0.79%
Healthcare
Other
After hours
$25.36▲ +0.00%
Sep 11, 7:30 PM ET
Volume 526.8K
Avg Volume (10D) 539.0K
Key Metrics & Fundamentals
Market Cap
$1.01B
P/E Ratio
72.5
Div Yield
–%
52W Range
18.80 - 27.66
% vs 50 MA
-0.38%
% vs 200 MA
6.27%
RSI-14
48.9
MACD Histogram
-0.0200
Beta (1Y vs SPY)
0.35
Free Cash Flow
$56.12M
Gross Rev
$192.40M
Gross Profit
$148.24M
EBITDA
$34.55M
COGS
$44.16M
Operating Exp
$136.37M
Operating Income
$11.86M
EBIT
$11.86M
Pretax Income
$2.56M
Net Income
$4.65M
EPS (Diluted)
0.12
Price & Volume History
Loading chart…
Recent News
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 9, 2026 12:00 PM
Leerink Partners Initiates Coverage on Pacira Biosciences With Market Perform Rating, $28 Price Target
MT Newswires · Sep 9, 2026 11:46 AM
Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?
Zacks · Sep 4, 2026 3:30 PM
Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?
Zacks · Sep 3, 2026 3:30 PM
PharmaCorp Rx Inc. Announces Board and Committee Changes
GlobeNewswire · Aug 27, 2026 11:30 AM
Pacira (PCRX) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 12, 2026 2:42 PM
Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?
Simply Wall St. · Aug 10, 2026 6:10 AM
Pacira BioSciences (PCRX) Could Be 35% Undervalued On Phase 1 Gene Therapy Progress
Simply Wall St. · Aug 6, 2026 9:14 PM
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
GlobeNewswire · Aug 6, 2026 12:00 PM
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut
Zacks · Aug 5, 2026 4:16 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See PCRX's money flow as a full page
Social Sentiment
No Reddit posts found for PCRX.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.